Respiratory

Latest News

Nerandomilast is an investigational oral, preferential inhibitor of phosphodiesterase 4B that has shown promise in IPF and PPF. | Image credit: Елена Бутусова - stock.adobe.com

Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD

February 13th 2025

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

Sanofi | Image credit: Eagle - stock.adobe.com

Combination Influenza and COVID-19 Vaccine Candidates Granted Fast Track Designation

By Pearl Steinzor

December 16th 2024

Group of diverse kids | Image Credit: © EKKAPON-stock.adobe.com

Ambient Toxins Linked to Disabilities in Minority Schoolchildren

By Maggie L. Shaw

December 10th 2024

RSV vaccine | Image credit: Pawel - atock.adobe.com

Nirsevimab Protected Infants, Children From Severe RSV in 2023–2024 Season

By Pearl Steinzor

December 6th 2024

Doctor with an image of lungs | Image credit: lungs_PRASANNAPIX

Key Flu and RSV Recommendations for the 2024-2025 Respiratory Virus Season

By Lauren Biscaldi, MS

November 26th 2024

Continuing Medical Education

View All

March 23rd 2025

Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies

1.0 Credit / Immunology, Pulmonology/Respiratory

...

18 19 20 21 22

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions